Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab

Budigalimab, a novel anti–PD-1 monoclonal antibody, demonstrated efficacy and biomarker pharmacodynamics in patients with head and neck squamous cell carcinoma (HNSCC) or non–small cell lung cancer (NSCLC) consistent with those reported by other PD-1 inhibitors. Herein are presented additional outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambert, Stacie L., Zhang, Chun, Guo, Claire, Turan, Tolga, Masica, David L., Englert, Stefan, Fang, Yuni, Sheridan, James, McLaughlin, Robert Tyler, Tribouley, Catherine, Vosganian, Greg, Afar, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906246/
https://www.ncbi.nlm.nih.gov/pubmed/35034046
http://dx.doi.org/10.1097/CJI.0000000000000408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906246/
https://www.ncbi.nlm.nih.gov/pubmed/35034046
http://dx.doi.org/10.1097/CJI.0000000000000408

Ejemplares similares